

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Zuranolone for treating severe postnatal depression ID6431

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
0	submit or appeal)
Company	General
Biogen (Zuranolone)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Postpartum PsychosisAssociation for Post Natal Illness	Board of Community Health Councils in Wales
Association of Mental Health	British National Formulary
Providers	Care Council for Wales
D: 1 1117	
	Care Quality Commission Department of Health Month and Incland
	Department of Health - Northern Ireland Orfole
Child Bereavement UK Dannessian LIK	Gofal
Depression UK	Hafal
Maternal Mental Health Alliance	Healthcare Improvement Scotland
Mental Health Foundation	Medicines and Healthcare products
Mental Health Matters	Regulatory Agency
• MIND	MIND Cymru
National Childbirth Trust	National Association of Primary Care
• PANDAS	National Pharmacy Association
PAPYRUS	NHS Confederation
Race Equality Foundation	Scottish Medicines Consortium
Rethink	Social Care Institute for Excellence
 Sands - Stillbirth and neonatal death 	Welsh Government
charity	Welsh Health Specialised Services
SANE	Committee
South Asian Health Foundation	
Specialised Healthcare Alliance	Possible comparator companies
The Matthew Trust	Accord Healthcare (amitriptyline,
WISH - A Voice for women's mental	citalopram, duloxetine, escitalopram,
health	imipramine, lofepramine, mirtazapine,
	fluoxetine, paroxetine, quetiapine,
Healthcare professional groups	sertraline and venlafaxine)
British Association for Counselling and	Amneal Pharma Europe (duloxetine,
Psychotherapy	paroxetine)
British Association for	Aristo Pharma (quetiapine)
Psychopharmacology	AstraZeneca (quetiapine)
British Association of Behavioural and	Aurobindo Pharma (citalopram,
Cognitive Psychotherapies	duloxetine, escitalopram, fluoxetine,

Provisional stakeholder list for the evaluation of zuranolone for treating severe postnatal depression ID6431



Provisional Consultees Provisional Commentators (no right to submit or appeal) mirtazapine, paroxetine, quetiapine. **British Association of Occupational** Therapists and College of sertraline and venlafaxine) Occupational Therapists Chiesi (venlafaxine) • Consilient Health (duloxetine, **British Association of Social Workers** escitalopram, quetiapine and **British Geriatrics Society** venlafaxine) British Neuropsychiatry Association Creo Pharma (Iofepramine and British Psychoanalytic Council trazodone) British Psychological Society • Dexcel Pharma (venlafaxine) British Psychotherapy Foundation Dr Reddys Labs (duloxetine, fluoxetine College of Mental Health Pharmacy and sertraline) Counsellors and Psychotherapists in Fontus heath (quetiapine) **Primary Care** GlaxoSmithKline (paroxetine) Health and Care Professions Council HBS Healthcare (duloxetine) Mental Health Nurses Association King Pharmaceuticals (nortriptyline) Primary Care Mental Health Education Kyowa Kirin (phenelzine) Royal College of General Practitioners Lilly UK (duloxetine and fluoxetine) Royal College of Nursing Lundbeck (citalopram, escitalopram, Royal College of Pathologists vortioxetine) Royal College of Physicians Lupin (sertraline) Royal College of Psychiatrists Marlborough (doxepin) Royal Pharmaceutical Society Merck Sharp & Dohme (mirtazapine) Royal Society of Medicine Mylan (citalopram, clomipramine, **UK Clinical Pharmacy Association** escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, Others paroxetine, quetiapine, trazodone and Department of Health and Social Care venlafaxine) NHS England Par Laboratories Europe (fluoxetine) Pfizer (reboxetine, sertraline and venlafaxine) Rivopharm (citalopram, trazodone) Sandoz (citalopram, paroxetine and quetiapine) Servier (agomelatine) Sun Pharmaceuticals (sertraline and venlafaxine) Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine,

Provisional stakeholder list for the evaluation of zuranolone for treating severe postnatal depression ID6431

imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline,


Wockhardt (amitriptyline, fluoxetine,

trazodone and venlafaxine)

fluvoxamine, mirtazapine and

venlafaxine)

Issue date: September 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine)
	 Relevant research groups Campbell Collaboration Social Welfare Group Careif Cochrane Depression Anxiety and Neurosis Group Critical Psychiatry Network Genomics England Health Services Research Unit, Department of Public Health, University of Oxford Institute of Psychiatry Joseph Rowntree Foundation MRC Clinical Trials Unit National Institute for Health Research National Primary Care Research & Development Centre
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of zuranolone for treating severe postnatal depression ID6431

Issue date: September 2024





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.